PMID- 33592881
OWN - NLM
STAT- MEDLINE
DCOM- 20210223
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 5
DP  - 2021 Feb 5
TI  - The efficacy and safety of Xuebijing injection in the treatment of radiation 
      pneumonitis: A protocol for systematic review and meta-analysis.
PG  - e24344
LID - 10.1097/MD.0000000000024344 [doi]
LID - e24344
AB  - BACKGROUND: At present, the treatment of radiation pneumonitis (RP) is still a 
      clinical problem. Although a variety of drugs such as glucocorticoids and 
      antibiotics are used for RP treatment, side effects remain to be inevitable. 
      Xuebijing injection (XBJ), a Chinese herbal injection, has been widely used in RP 
      treatment, but there is no published systematic review to evaluate its efficacy 
      and safety. METHODS: Based on Preferred Reported Items for Systematic Review and 
      Meta-analysis guidelines, we will conduct this systematic review and 
      meta-analysis. Related randomized controlled trials will be searched in 7 
      databases: PubMed, Cochrane Library, EMBASE, China National Knowledge 
      Infrastructure, WANFANG database, SinoMED, and China Science and Technology 
      Journal Database from inception of the library to October 1, 2020. Two 
      researchers will independently carry out literature screening, data extraction, 
      and bias risk assessment. The primary outcome is total effective rate and the 
      secondary outcome is inflammation-related indicators such as C-reactive protein, 
      tumor necrosis factor alpha, interleukin-6, interleukin-10, etc and adverse 
      events. Cochrane Review Manager (RevMan 5.3) software will be applied to analyze 
      the data and generate forest plot and funnel plot. RESULTS: This study will 
      provide a synthesis of current evidence of XBJ in RP treatment including total 
      effective rate and inflammation-related indicators such as CRP, TNF-alpha, IL-6, 
      IL-10, etc. and adverse events (AEs). CONCLUSION: This systematic review and 
      meta-analysis will objectively evaluate the efficacy and safety of XBJ in the 
      treatment of RP, and provide evidence for the application of XBJ in RP treatment. 
      SYSTEMATIC REVIEW REGISTRATION NUMBER: INPLASY2020120037.
CI  - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Li, Zheng
AU  - Li Z
AD  - Guang'an Men Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
FAU - Wang, Dandan
AU  - Wang D
FAU - Zhang, Ying
AU  - Zhang Y
FAU - Wang, Shuo
AU  - Wang S
FAU - Wang, Xueqian
AU  - Wang X
FAU - Li, Yuxiao
AU  - Li Y
FAU - Gui, Yuerong
AU  - Gui Y
FAU - Dong, Jun
AU  - Dong J
FAU - Hou, Wei
AU  - Hou W
LA  - eng
GR  - K858/Evidence-Based Research Scheme Design of Traditional Chinese Medicine for 
      Malignant Tumor/
GR  - 82004179/National Natural Science Foundation of China/
GR  - 7192181/Natural Science Foundation of Beijing Municipality/
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Xuebijing)
SB  - IM
MH  - Adult
MH  - Drugs, Chinese Herbal/*administration & dosage
MH  - Female
MH  - Humans
MH  - Injections
MH  - Male
MH  - Meta-Analysis as Topic
MH  - Radiation Pneumonitis/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - Treatment Outcome
PMC - PMC7870166
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2021/02/18 06:00
MHDA- 2021/02/24 06:00
PMCR- 2021/02/05
CRDT- 2021/02/17 01:02
PHST- 2020/12/18 00:00 [received]
PHST- 2020/12/28 00:00 [accepted]
PHST- 2021/02/17 01:02 [entrez]
PHST- 2021/02/18 06:00 [pubmed]
PHST- 2021/02/24 06:00 [medline]
PHST- 2021/02/05 00:00 [pmc-release]
AID - 00005792-202102050-00068 [pii]
AID - MD-D-20-12408 [pii]
AID - 10.1097/MD.0000000000024344 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Feb 5;100(5):e24344. doi: 10.1097/MD.0000000000024344.